Sorry, I don't understand your search. ×
Back to Search Start Over

Temporal Dynamics of Serum Perforin and Granzyme during the Acute Phase of SARS-CoV-2 Infection

Authors :
MD Tazikur Rahman
Sukhyun Ryu
Chiara Achangwa
Joo-Hee Hwang
Jeong-Hwan Hwang
Chang-Seop Lee
Source :
Vaccines, Vol 11, Iss 8, p 1314 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

Background: As many SARS-CoV-2 infections are asymptomatic, it could be useful to be able to determine how much time has passed since infection. We explored the changes in the temporal levels of T cell-related proteins (including perforin and granzymes) in the sera of patients with SARS-CoV-2 infection using a commercially available assay. Methods: This study enrolled 36 patients infected with SARS-CoV-2 and 20 healthy control participants. Blood samples were collected at three different times based on the number of days since symptom onset (early phase: 1–5 days, mid-phase: 6–10 days, late phase: 11–18 days). We assessed the temporal changes in the serum levels of perforin and granzymes in patients with SARS-CoV-2 infection by comparing the results with those obtained in the healthy control group. Results: We identified a significantly low level of perforin in the early phase of SARS-CoV-2 infection (p < 0.01), which was restored to normal during the mid- and late phases of the infection. However, there was no difference in the temporal change in the level of granzymes in SARS-CoV-2-infected patients compared to the healthy control group. Conclusions: This finding suggests that SARS-CoV-2 infection paralyzed the perforin expression in the early period immediately after infection. Thus, serum perforin is a potential marker for identifying the acute phase of SARS-CoV-2 infection.

Details

Language :
English
ISSN :
2076393X
Volume :
11
Issue :
8
Database :
Directory of Open Access Journals
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
edsdoj.458f34aa4a184fd4b1301c7c98e9a36f
Document Type :
article
Full Text :
https://doi.org/10.3390/vaccines11081314